368 related articles for article (PubMed ID: 31753738)
1. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
[TBL] [Abstract][Full Text] [Related]
2. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
Massari F; Di Nunno V; Guida A; Costa Silva CA; Derosa L; Mollica V; Colomba E; Brandi G; Albiges L
Clin Genitourin Cancer; 2021 Feb; 19(1):32-40. PubMed ID: 32694008
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
Mollica V; Rizzo A; Tassinari E; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Anticancer Drugs; 2021 Jan; 32(1):74-81. PubMed ID: 33290315
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
6. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
7. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay RR; Kroeger N; Xie W; Lee JL; Knox JJ; Bjarnason GA; MacKenzie MJ; Wood L; Srinivas S; Vaishampayan UN; Rha SY; Pal SK; Donskov F; Tantravahi SK; Rini BI; Heng DY; Choueiri TK
Eur Urol; 2014 Mar; 65(3):577-84. PubMed ID: 23962746
[TBL] [Abstract][Full Text] [Related]
8. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
11. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy.
Kim SH; Kim JK; Park EY; Joo J; Lee KH; Seo HK; Joung JY; Chung J
PLoS One; 2019; 14(2):e0211105. PubMed ID: 30785902
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.
Tanaka N; Mizuno R; Yasumizu Y; Ito K; Shirotake S; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Urol Oncol; 2017 Feb; 35(2):39.e19-39.e28. PubMed ID: 27825515
[TBL] [Abstract][Full Text] [Related]
13. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
[TBL] [Abstract][Full Text] [Related]
15. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
[TBL] [Abstract][Full Text] [Related]
16. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
18. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
[TBL] [Abstract][Full Text] [Related]
19. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
Derosa L; Bayar MA; Albiges L; Le Teuff G; Escudier B
Angiogenesis; 2019 Aug; 22(3):383-395. PubMed ID: 30739258
[TBL] [Abstract][Full Text] [Related]
20. Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Donskov F; Xie W; Overby A; Wells JC; Fraccon AP; Sacco CS; Porta C; Stukalin I; Lee JL; Koutsoukos K; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim HW; Rathi N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC
Eur Urol Oncol; 2020 Aug; 3(4):530-539. PubMed ID: 32037304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]